Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 2/2005

01-02-2005 | Original Article

Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution

Authors: S. Müller, P. Schütt, P. Bojko, M. R. Nowrousian, J. Hense, S. Seeber, T. Moritz

Published in: Annals of Hematology | Issue 2/2005

Login to get access

Abstract

Hemolytic uremic syndrome (HUS) has been described following the administration of multiple antineoplastic agents, most notably mitomycin C. More recently, several cases of gemcitabine-induced HUS have been observed with the overall incidence of gemcitabine-induced HUS estimated at 0.015–0.25%. We here report on four patients who developed HUS following gemcitabine therapy at our institution within the last year (incidence 1.4%). All these patients had advanced-stage disease, were heavily pretreated, and received prolonged gemcitabine application, suggesting that in this subgroup of patients HUS may be more frequently encountered than documented so far.
Literature
1.
Allford SL, Hunt BJ, Rose P, Machin SJ (2003) Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 120:556–573CrossRefPubMed
2.
Bell WR, Braine HG, Ness PM, Kickler TS (1991) Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 325:398–403PubMed
3.
Borghardt EJ, Kirchertz EJ, Marten I, Fenchel K (1998) Protein A-immunoadsorption in chemotherapy associated hemolytic-uremic syndrome. Transfus Sci 19 [Suppl]:5–7CrossRefPubMed
4.
Brodowicz T, Breiteneder S, Wiltschke C, Zielinski CC (1997) Gemcitabine-induced hemolytic uremic syndrome: a case report. J Natl Cancer Inst 89:1895–1896CrossRefPubMed
5.
Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J (1999) A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 85:2023–2032PubMed
6.
Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R (1955) Hemolytic-uremic syndrome: bilateral kidney cortex necrosis in acute acquired hemolytic anemia, Schweiz Med Wochenschr 85:905–909PubMed
7.
Gordon LI, Kwaan HC (1997) Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 34:140–147PubMed
8.
Guchelaar HJ, Richel DJ, van Knapen A (1996) Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer Treat Rev 22:15–31CrossRefPubMed
9.
Hui YF, Reitz J (1997) Gemcitabine: a cytidine analogue active against solid tumors. Am J Health Syst Pharm 54:162–170 (quiz 197-198)PubMed
10.
Lesesne JB, Rothschild N, Erickson B, Korec S, Sisk R, Keller J, Arbus M, Woolley PV, Chiazze L, Schein PS et al (1989) Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 7:781–789PubMed
11.
Melnyk AM, Solez K, Kjellstrand CM (1995) Adult hemolytic-uremic syndrome. A review of 37 cases. Arch Intern Med 155:2077–2084CrossRefPubMed
12.
Meyrier A, Becquemont L, Weill B, Callard P, Rainfray M (1991) Hemolytic-uremic syndrome with anticardiolipin antibodies revealing paraneoplastic systemic scleroderma. Nephron 59:493–496PubMed
13.
Palmisano J, Agraharkar M, Kaplan AA (1998) Successful treatment of cisplatin-induced hemolytic uremic syndrome with therapeutic plasma exchange. Am J Kidney Dis 32:314–317PubMed
14.
Remuzzi G, Ruggenenti P (1995) The hemolytic uremic syndrome. Kidney Int 48:2–19PubMed
15.
Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325:393–397PubMed
16.
Schiebe ME, Hoffmann W, Belka C, Bamberg M (1998) Mitomycin C-related hemolytic uremic syndrome in cancer patients. Anticancer Drugs 9:433–435PubMed
17.
Schieppati A, Ruggenenti P, Cornejo RP, Ferrario F, Gregorini G, Zucchelli P, Rossi E, Remuzzi G (1992) Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome. The Italian Registry of Haemolytic Uremic Syndrome. J Am Soc Nephrol 2:1640–1644PubMed
18.
Segonds A, Louradour N, Suc JM, Orfila C (1979) Postpartum hemolytic uremic syndrome: a study of three cases with a review of the literature. Clin Nephrol 12:229–242PubMed
19.
Serke S, Riess H, Oettle H, Huhn D (1999) Elevated reticulocyte count—a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report. Br J Cancer 79:1519–1521CrossRefPubMed
20.
Siegler RL (1995) The hemolytic uremic syndrome. Pediatr Clin North Am 42:1505–1529PubMed
21.
Snyder HW, Jr., Mittelman A, Oral A, Messerschmidt GL, Henry DH, Korec S, Bertram JH, Guthrie TH, Jr., Ciavarella D, Wuest D et al (1993) Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. Cancer 71:1882–1892PubMed
22.
Verwey J, Boven E, van der Meulen J, Pinedo HM (1984) Recovery from mitomycin C-induced hemolytic uremic syndrome. A case report. Cancer 54:2878–2881PubMed
23.
von Baeyer H (2002) Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. Ther Apher 6:320–328CrossRefPubMed
Metadata
Title
Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution
Authors
S. Müller
P. Schütt
P. Bojko
M. R. Nowrousian
J. Hense
S. Seeber
T. Moritz
Publication date
01-02-2005
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 2/2005
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-004-0938-8

Other articles of this Issue 2/2005

Annals of Hematology 2/2005 Go to the issue

Original Article

IgD multiple myeloma—a clinical profile and outcome with chemotherapy and autologous stem cell transplantation

Letter to the Editor

Cerebral venous thrombosis in a patient with Evans syndrome: a rare association

Letter to the Editor

Cytogenetic response to pipobroman in Philadelphia-positive chronic myeloid leukemia with thrombocythemic onset

Letter to the Editor

Vancomycin-resistant Staphylococcus aureus in a bone marrow transplantation unit

Letter to the Editor

Pure red cell aplasia with a clonal T-cell disorder

Original Article

Protein C system defects in Indian children with thrombosis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits